Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPDET: Dexmedetomidine Post-Thrombectomy in Stroke
NCT04916197Phase 4Recruiting
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dexmedetomidine in ischemic stroke (2 arms), sponsored by Beijing Chaoyang Hospital. Primary endpoint: The favorable functional outcome of stroke-related disability rate at 90 days. Started Mar 2024; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04916197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04916197.